The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year
Moreover, most current studies are based on small rodent models, with limited validation in large animal models or organoid systems
Are There Specific Risk Factors That Make a Rash More Likely with Tirzepatide
However, a re-analysis of their data found an abnormal ratio of mercury in blood to mercury in hair, suggesting an excretion problem [16]
Hormone Metabolic Res
Indeed, GIPR agonism can blunt the nauseating effects of GLP-1R agonists in humans (52)